GCGiovanni Cassola

Giovanni Cassola

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giovanni Cassola has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area

    by Maria L. Cristina, Cristiano Alicino, Marina Sartini, Valeria Faccio, Anna M. Spagnolo, Valerio D. Bono, Giovanni Cassola, Anna M. De Mite, Maria P. Crisalli, Gianluca Ottria, et al.


  • Open Access

    Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?

    by Antonio Di Biagio, Marta Ameri, Davide Sirello, Giovanni Cenderello, Enrico Di Bella, Lucia Taramasso, Barbara Giannini, Mauro Giacomini, Claudio Viscoli, Giovanni Cassola, et al.

    In the last 20 years routine T CD4+ lymphocyte (CD4+) cell count has proved to be a key factor to determine the stage of HIV infection and start or discontinue of prophylaxis for opportunistic infections. However, several studies recently showed that in stable patients on cART a quarterly CD4+ cell count monitoring results in limited (or null) clinical relevance. The research is intended to investigate whether performing quarterly CD4+ cell counts in stable HIV-1 patients is still recommendable and to provide a forecast of the cost saving that could be achieved by reducing CD4+ monitoring in such a category of patients. The study is based on data referring to all HIV-infected patients > 18 years of age being treated at two large infectious diseases units located in the metropolitan area of Genoa, Italy. The probability of CD4+ cell counts dropping below a threshold value set at 350 cells/mm3 is assessed using confidence intervals and Kaplan-Meier survival estimates, whereas multivariate Cox analysis and logistic regression are implemented in order to identify factors associated with CD4+ cell count falls below 350 cells/mm3. Statistical analysis reveals that among stable patients the probability of maintaining CD4+ >350 cell/mm3 is more than 98%. Econometric models indicate that HCV co-infection and HIV-RNA values >50 copies/mL in previous examinations are associated with CD4+ falls below 350 cells/mm3. Moreover, results suggest that the cost saving that could be obtained by reducing CD4+ examinations ranges from 33 to 67%. Empirical findings shows that patients defined as stable at enrollment are highly unlikely to experience a CD4+ value <350 cell/mm3 in the space/arc of a year. The research supports a recommendation for annual CD4+ monitoring in stable HIV-1 patients.


    • 23 August 2016
      • Vol. 39  (4) , 299-300

    Increasing use and accessibility of anti parasitic drugs for migrants with neglected diseases at a time of migratory emergency.

    by Giovanni Cenderello, Antonio Di Biagio, Niccolò Riccardi, Lucia Taramasso, Andrea De Maria, Giovanni Cassola, Claudio Viscoli

    This work focused on Schistosoma spp. as a potential agent of gross haematuria in non endemic areas. This change in epidemiology is mainly due to recent migratory flows. Moreover it emphasized the needfor cultural action (aimed at Urologists, Dermatologists, General Practitioners and Emergency Medicine doctors) to provide the elements for a correct and timely diagnosis. But the most important issue raised by this paper is the call for a fast track supply of drugs (usually not available in Italy) to field operators for treating tropical diseases.


  • Therapeutic Management of Chronic Hepatitis B in Clinical Practice

    by Edoardo G. Giannini, Simona Marenco, Silvia Boni, Andrea Beltrame, Laura A. Nicolini, Lucia Taramasso, Marcello Feasi, Alessandro Grasso, Pasqualina De Leo, Gianfranco Percario, et al.

    To characterize the clinical and treatment pattern in a large population of hepatitis B virus (HBV) patients managed at tertiary referral centers in clinical practice. Successful treatment, either with interferon (IFN) or nucleos(t)ide analogs (NUCs), of chronic HBV infection is associated with improved long-term patient outcome. However, in clinical practice, the actual management of these patients is not well characterized, and data regarding treatment pattern in this setting are lacking. In this cross-sectional study, we evaluated 505 patients chronically infected with HBV alone and who had at least 1-year follow-up. We assessed indication to, rate of, and type of treatment as well as the characteristics of treated patients. Overall prevalence of positivity for HBe antigen was 19.3%, and the majority of patients had chronic hepatitis (47.5%). Non-Italian patients represented approximately one third of the population (27.1%). Among patients with indication to antiviral therapy (n=318), treatment was actually carried out in 264 patients (83.0%), prevalently with NUCs (65.9%). IFN-treated patients were younger (P<0.001), more frequently male (P=0.025) and HBeAg positive (P=0.003), and less frequently cirrhotics (P<0.001) as compared with patients treated with NUCs. In a geographical area with a low positivity for HBe antigen, antiviral therapy is actually carried out in the majority of patients who have indication to treatment, prevalently with NUCs, whereas IFN treatment is more frequently carried out in young, HBe antigen-positive patients who do not have advanced liver disease.


  • Open Access

    Specific Issues in the Management of Hepatocellular Carcinoma in Hepatitis B Virus/Hepatitis C Virus-Human Immunodeficiency Virus Co-infected Patients

    by Emanuele Pontali, Giovanni Cenderello, Giovanni Cassola, Augusta Torresin

    Hepatocellular carcinoma (HCC) has become in recent years a leading cause of morbidity and mortality in patients with HIV who are co-infected with HBV/HCV. The aim of this review is to describe the peculiarities of HCC occurring in this highly demanding scenario, covering all topics from diagnosis to treatment. The epidemiology of co-infection with hepatitis B and C is covered. The following sections deal with suggestions and recommendations about screening, diagnosis and treatment. The key role of liver ultrasound imaging and serum alpha-fetoprotein determination for HCC early diagnosis in patients at high risk for HCC development is underscored. All current treatments of HCC in this special population are described and commented, i.e. surgical resection, percutaneous ethanol injection, radiofrequency ablation, transarterial chemoembolization, targeted therapy, liver transplant. Special consideration has been given to the issues hindering the access of HIV patients with HCC to liver transplantation programmes. We hint to the much awaited availability of highly efficacious anti-HCV Directly Active Antivirals. In fact, the advent of these molecules is likely to produce a deep impact on and a dramatic improvement of the natural history of HIV/HCV co-infections. In summary, HCC incidence in patients with HIV who are co-infected with HBV/HCV is on the rise. Early diagnosis is essential to treat patients with the most efficacious treatment options. Treatment of all three viral infections is the key intervention to prevent occurrence of HCC in this population. Nevertheless, large prospective trials are badly needed to assess the optimal management of patients who have cleared HCV but still risk to develop a liver malignancy.


    • 1 January 2015
      • Vol. 210, 241-5

    IANUA: a regional project for the determination of costs in HIV-infected patients.

    by Barbara Giannini, Roberta Gazzarata, Patrizia Orcamo, Caterina Merlano, Giovanni Cenderello, Alberto Venturini, Antonio Di Biagio, Giovanni Mazzarello, Marcello Montefiori, Marta Ameri, et al.

    HIV treatment is based on combined antiretroviral therapy (cART) which has substantially improved survival, thus resulting in an increase in patient life expectancy as well as in the cost of HIV-related medical care. Therefore, several cost effectiveness studies were implemented worldwide, with one specifically in the Liguria region (Italy), to compare the annual economic expense in this area for HIV services, and the related improvement in patients' health. The IANUA project is intended to implement both cost-effectiveness and cost-utility analysis, therefore data related to clinical indicators and perceived health status were collected, the latter using a questionnaire based on the EQ-5D-3L. Information about the antiretroviral drugs and the relative quantity that a patient withdraws from the hospital pharmacy every month were extracted from the regional "F-file". All data gathered were stored in the Ligurian HIV Network, a web platform developed by the DIBRIS - Medinfo laboratory. More than eight hundred questionnaires were collected, and data will be elaborated by economists and psychologists. The first statistical elaborations showed that, as expected, costs increased as the number of therapeutic lines increased. Moreover, the average annual costs for patients whose last CD4 values were below 200 cells/mmc corresponded to the maximum expense recorded, however, the cost for patients with final CD4 counts above 500 cells/mmc was not, as expected, the lowest found. This can be explained by the fact that stabilized patients, who had CD4 values below 500 cells/mmc, did not need very expensive care, while patients with CD4 counts above 500 cells/mmc improved their health status thanks to cART.


  • An unexpected Streptococcus pneumoniae strain

    by Giovanni Cenderello, Emanuele Pontali, Augusta Torresin, Giulia Milano, Filippo Ansaldi, Marcello Feasi, David Usiglio, Marco Mori, Giancarlo Icardi, Giovanni Cassola

    This clinical driven report describes the unexpected detection of a multidrug resistant (MDR) Streptococcus pneumoniae strain. Italy is usually considered a country characterized by a low prevalence of MDR S. pneumoniae. We describe the occurrence of bacterial meningitis sustained by a MDR S. pneumoniae strain in Italy. The first-line treatment was started with ceftriaxone and dexamethasone, but after the identification of such a resistant strain a second-line regimen was needed. The new regimen was chosen on both susceptibility and pharmacokinetic criteria. Linezolid and levofloxacin were started and a dramatic improvement was observed. A more sensitive anamnesis revealed some elements known to be associated to a MDR S. pneumoniae occurrence (immunesuppression, former antibiotic therapy). So this case should pinpoint our attention on risk factors of MDR for a careful choice of antibiotic therapy in serious pneumococcal infections.

  • Open Access

    Varied spectrum of clinical presentation and mortality in a prospective registry of visceral leishmaniasis in a low endemicity area of Northern Italy

    by Giovanni Cenderello, Ambra Pasa, Andrea Dusi, Chiara Dentone, Federica Toscanini, Nicoletta Bobbio, Elisabetta Bondi, Valerio Del Bono, Manuela Izzo, Giovanni Riccio, et al.

    Background: Visceral Leishmaniasis (VL) is endemic in 88 countries, in areas of relatively low incidence with a relevant proportion of immune suppressed patients clinical presentation, diagnosis and management may present difficulties and pitfalls. Methods: Demographic data, clinical, laboratory features and therapeutic findings were recorded in patients identified by a regional VL disease registry from January 2007 to December 2010. Results: A total of 55 patients (36 adults mean age 48.7 years, 19 children median age 37.5 months) were observed presenting with 65 episodes. All childen were immunocompetent, whereas adults affected by VL included both immunocompetent (n°17) and immunesuppressed (n°19) patients. The clinical presentation was homogeneous in children with predominance of fever and hepato-splenomegaly. A wider spectrum of clinical presentations was observed in immunocompromised adults. Bone marrow detection of intracellular parasites (Giemsa staining) and serology (IFAT) were the most frequently used diagnostic tools. In addition, detection of urinary antigen was used in adult patients with good specificity (90%). Liposomal amphotericin B was the most frequently prescribed first line drug (98.2% of cases) with 100% clinical cure. VL relapses (n°10) represented a crucial finding: they occurred only in adult patients, mainly in immunocompromised patients (40% of HIV, 22% of non-HIV immunocompromised patients, 5,9% of immunocompetent patients). Furthermore, three deaths with VL were reported, all occurring in relapsing immunocompromised patients accounting for a still high overall mortality in this group (15.8%). Conclusions: The wide spectrum of clinical presentation in immunesuppresed patients and high recurrence rates still represent a clinical challenge accounting for high mortality. Early clinical identification and satisfactory treatment performance with liposomal amphotericin B are confirmed in areas with low-level endemicity and good clinical standards. VL needs continuing attention in endemic areas where increasing numbers of immunocompromised patients at risk are dwelling.